Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04152642
Recruitment Status : Completed
First Posted : November 5, 2019
Results First Posted : February 2, 2021
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
Procter and Gamble

Brief Summary:
The objective of this pilot study is to determine if an experimental mouth rinse and a marketed dry mouth rinse are more effective in relieving dry mouth compared to water.

Condition or disease Intervention/treatment Phase
Dry Mouth Device: Marketed Dry Mouth Rinse Other: Water control Device: Experimental Dry Mouth Rinse Not Applicable

Detailed Description:
This is a controlled, randomized, 3-treatment, 3-period crossover study in subjects with self-reported dry mouth symptoms as determined by subject responses (as determined by the response to "relieving the discomfort of dry mouth" question from the modified Product Performance and Attributes Questionnaire I/ Moisturization and Dryness (PPAQ I/ MD)) compared to water. Subjects enrollment is based on the responses to the Dry Mouth Inventory (DMI). A sufficient number of volunteers will be screened to ensure enrollment of up to 30 subjects at Acclimation. Subjects who meet the eligibility criteria will continue into the treatment phase of the study. Safety will be assessed by Oral examinations at Baseline/Day1 and Day 4. Subjects will complete questionnaires at Baseline (before product use Day 1 only), after immediate use, 30 minutes, 1 hour, 2 hours, and 4 hours after supervised product use on Day 1 and Day 4 of each period. The PPAQ II questionnaire will be completed in the morning of Day 4 of each period. Subjects will be randomly assigned to treatment sequences at the Baseline visit of Period 1. The treatment and washout periods will be repeated until all three treatment periods have been completed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: 3-treatment crossover, with 4 days of use
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Clinical Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse Compared to a Negative Control
Actual Study Start Date : November 4, 2019
Actual Primary Completion Date : December 5, 2019
Actual Study Completion Date : December 5, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dry Mouth

Arm Intervention/treatment
Active Comparator: Marketed Mouth Rinse
dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
Device: Marketed Dry Mouth Rinse
relieves dry mouth symptoms by physically coating oral mucosal surfaces.

Experimental: Experimental Mouth Rinse
dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
Device: Experimental Dry Mouth Rinse
relieves dry mouth symptoms by physically coating oral mucosal surfaces.

Sham Comparator: Water/Negative Control
subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
Other: Water control
negative control




Primary Outcome Measures :
  1. Product Performance and Attributes (PPAQ I) Question #1: 2-hr at Day 4 [ Time Frame: 2-hour, Day 4 ]

    Product Performance and Attributes (PPAQ I) Question #1:

    Since you have been used the product, please rate each of the following at this timepoint: (Select one response for each attribute)- excellent=5, very good=4, good=3, fair=2, poor=1:

    1) Relieves the discomfort of your dry mouth




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
  • Be at least 18 years of age;
  • Be in good general health as determined by the Investigator/designee;
  • Agree not to participate in any other oral care studies for the duration of this study;
  • Agree to delay elective dentistry, including dental prophylaxis, until study completion, and to report any non-study dentistry received during the course of the study;
  • Agree to refrain from the use of any non-study oral hygiene products for the study duration including mouth rinse and toothpaste (flossing is permitted if part of their normal routine);
  • Self-report a dry mouth feeling according to the modified DMI questions. (Subject must answer at least 2 out of 4 questions with 'agree a little,' 'agree' or 'strongly agree');
  • Agree to refrain from smoking, drinking, using tobacco products, using breath mints, medicated lozenges, or chewing gum during the 4-hour test period;
  • Agree to return for all scheduled visits and to follow all study procedures.

Exclusion Criteria:

  • Any condition or disease, as determined by the Investigator/Designee, that could be expected to interfere with examination procedures, with compliance, or with the subject's safe completion of the study;
  • Severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession;
  • Active treatment for periodontitis;
  • Having a history of allergies or hypersensitivity to mouth rinse or ingredients in commercial dental products or cosmetics;
  • Self-reported pregnancy or the intent to become pregnant during the study, or breast feeding;
  • Full or partial dentures or any orthodontic appliances such as braces or aligners, or tongue or mouth piercing;
  • Having diabetes;
  • Inability to undergo any study procedure;
  • Having untreated oral mucosal disease which in the opinion of the investigator could interfere with the study (e.g., current oral ulceration);
  • Use of prescription systemic parasympathetic medications (e.g., Pilocarpine), for the treatment of the feeling of dry mouth;
  • Currently under the care of a dental/medical professional specifically for the treatment of dry mouth (at the discretion of the Investigator/Designee);
  • Self-reported mouth breathers (i.e., mouth breathing secondary to nasal obstruction);
  • Evidence of gross intra-oral neglect or need for extensive dental therapy; or
  • Currently undergoing radiotherapy and/or chemotherapy treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04152642


Locations
Layout table for location information
United States, Ohio
Procter & Gamble
Mason, Ohio, United States, 45040
Sponsors and Collaborators
Procter and Gamble
Investigators
Layout table for investigator information
Principal Investigator: Malgorzata Klukowska, DDS Procter and Gamble
  Study Documents (Full-Text)

Documents provided by Procter and Gamble:
Layout table for additonal information
Responsible Party: Procter and Gamble
ClinicalTrials.gov Identifier: NCT04152642    
Other Study ID Numbers: CSD2019138
First Posted: November 5, 2019    Key Record Dates
Results First Posted: February 2, 2021
Last Update Posted: February 2, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases